Optinose announced that it has entered into a license agreement with Inexia whereby Inexia has obtained certain rights that will enable the use of Optinose’s exhalation delivery systems, or EDS, and other intellectual property in their effort to discover and develop novel therapies based on positive modulators of Orexin OX1 and OX2 for neurological diseases. Inexia was recently formed as part of a structured financing agreement between Japan-based Sosei Group and Medicxi. In exchange for this license, Optinose will receive an upfront payment and for each product developed under the license agreement is eligible to receive up to $8M of development milestone payments and up to $37M of sales milestone payments. In addition, Optinose is eligible for tiered, low-to-mid single digit royalties based on net sales of any products successfully developed and commercialized under the license agreement. Inexia will be responsible for all costs and activities related to the identification, development and commercialization of potential products under this license.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.